Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Investment friend checked into ONCY
View:
Post by HCallahann44 on Feb 09, 2021 1:02pm

Investment friend checked into ONCY

works for Merrill Lynch...he asked around with some of the folks in their biotech group...told me most what we already know...its too small for their group to buy...one product company...couple of pharmas partnered..yada yada. But he said his biotech guy looked at the stock and some of the published studies and wasn't super impressed...yea Pela works...but it has a very weak positive effect. The studies have been small and the results have not blown any doors off...just some small incremental changes---hey women with advanced breast cancer bought a few months yay! He says he thinks the stock will languish and that big pharma wont be in any rush to partner or buy the company out. There are just too many companies competing in the space...and many are better capitalized with deeper pipelines. I asked him about another investment of mine XCUR --he said that one looked a lot better...better financial structure...numerous drugs in development...backed by some smart money...of course it is languishing too...meanwhile SHOP ROKU MSTR are doubling and tripling almost every few weeks....Market is probably preparing for a steep correction after all this froth....so for those of us looking for life changing wealth out of ONCY----its just more waiting for Godot. ..
Comment by canadafan on Feb 09, 2021 7:22pm
All, one needs to do is click on a posters name & see his/her previous posts. Looks like to me 9/10 of your last ONC posts have been negative: Just saying: many who short stocks go to great lengths to find, negative slants to post about the targetted commpany. My M.O. is clear & obvious, I omw shares and want to see the company & hnce S.P do well. I also have a "broker friend ...more  
Comment by HCallahann44 on Feb 09, 2021 8:21pm
Canada---I am not short....I am long 35k shares...the story recounted by my broker friend is accurate. You may know better...but I have reviewed all the stuff on the ONCY website and found nothing to debunk anything my friend told me. He didn't say ONCY was overvalued...he simply said the studies were small and only mildly positive. What is he missing? We are a one trick pony ---our studies ...more  
Comment by westcoast1000 on Feb 09, 2021 9:14pm
We have one product but it has many many applications. We own the property rights to a mechanism to make your immune system much more active in both the primary and secondary responses, and then to invade cancer cells with a CI and kill them. It works on many cancer types, including metastatic disease.  Does that sound like it is worthwhile? Does that sound like it works in a "game ...more  
Comment by Normandt1965 on Feb 09, 2021 9:22pm
" But lets face it---the virus has only minor impacts so far. " Ahah funny guy. Double the number of survivals is not what we consider a minor impact. You should re read the last updates....
Comment by HCallahann44 on Feb 11, 2021 10:35am
"Double the number of survivals" ??? this is dishonest...the reason we are stuck in this range per my biotech analyst friend is that the studies have been small....and the results have small incremental improvements treatment rather than any slam dunk cures...Why would a Pharma throw billions at us when there are dozens of small biotechs working on the same solutions...they can just sit ...more  
Comment by Noscams on Feb 11, 2021 2:52pm
I think they are just a bunch of Chislers looking for cheap shares...
Comment by Normandt1965 on Feb 11, 2021 6:32pm
You are 100% right Canadafan.
Comment by Noscams on Feb 11, 2021 8:52pm
I second that . That giuy is just some Chisler trying to pick up cheap stocks . The guy is sn insult yo anyones intilligence . Maybe he should do some D.D. .
Comment by JohnnyYeg on Feb 09, 2021 8:33pm
There is a reason I block you out HCallahan, and that's because you are so unbelievably transparent and predictable. Your intention is so clear - especially when you come back with your own "recommendation". FOLKS, this is a PERFECT example of why you should do your own due diligence - exactly what Canadafan always recommends. WHENEVER come one says "I have a friend somewhere... ...more  
Comment by fasttrack5 on Feb 10, 2021 1:52am
No kidding I put that individual on ignore also. meanwhile not pumping however ONC is looking good. long and holding. fast(:
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities